Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | TYMP | P19971 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | UPP1 | Q16831 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11755028 | 1.00 | LMNA (0.36) | LMNAALDH1A1BCHEKDM4ETYMP | |
| SCHEMBL21392064 | 0.84 | ALDH1A1 (0.35) | LMNAALDH1A1KDM4ETYMP | |
| SCHEMBL18910006 | 0.79 | BCHE (0.36) | LMNABCHEKDM4EBACE1 | |
| SCHEMBL11524208 | 0.79 | LMNA (0.31) | LMNAALDH1A1 | |
| SCHEMBL23471378 | 0.77 | — | — | |
| SCHEMBL24292513 | 0.77 | — | — | |
| SCHEMBL1148704 | 0.77 | — | — | |
| Hydrochloric Acid SCHEMBL27915216 | 0.76 | LMNA (0.36) | LMNAALDH1A1TYMPTHRBUPP1 | |
| SCHEMBL2983074 | 0.76 | LMNA (0.36) | LMNAALDH1A1TYMPTHRBCYP2D6 | |
| SCHEMBL2232621 | 0.76 | LMNA (0.53) | LMNAALDH1A1KDM4ETYMPTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9359358-B2 | Cyclohexyl azetidine derivatives as JAK inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2016-06-07 | — | — | US | disclosed |
| US-20130045963-A1 | Cyclohexyl Azetidine Derivatives as JAK Inhibitors | INCYTE CORPORATION (US) | 2013-02-21 | — | — | US | disclosed |
| US-20080132500-A1 | Antibiotic compounds | MERCK SHARP & DOHME CORP. | 2008-06-05 | — | — | US | disclosed |
| US-20080132500-A1 | Antibiotic compounds | MERCK SHARP & DOHME CORP. | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045963-A1 | Cyclohexyl Azetidine Derivatives as JAK Inhibitors | JAK1, JAK2, JAK3 | LMNA 4827/4885ALDH1A1 2907/4885BCHE 3101/4885 |
| US-20080132500-A1 | Antibiotic compounds | NRDC, MRPL21, PEPD | LMNA 3549/4885ALDH1A1 3691/4885BCHE 3373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.